Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published February 2010
  • Article
  • Info & Metrics
  • PDF
Loading

Cancer Cell Line Evolution

Zhang et al., Page 336

Tumorigenesis is influenced by natural selection processes, thus molecular evolutionary methodologies could be useful for understanding cancer biology. Zhang and colleagues describe a phylogenetic analysis of 353 cancer cell lines based on the alignment of 3252 variant nucleotides from 494 genes from 353 cancer cell lines. Reconstructed phylogenetic trees clustered cell lines by shared DNA variant patterns rather than tissue, suggesting that certain diverse cancer types have similar oncogenic pathways. Positive selection analysis revealed specific DNA variants that might be potential driver mutations. Their study supports the broader application of evolutionary approaches in the analyses of the cancer genome.

RelA-Mediated Acquired Resistance to Lapatinib

Xia et al., Page 292

The clinical efficacy of lapatinib, a small molecule inhibitor of ErbB2 and EGFR tyrosine kinases, is limited by the development of therapeutic resistance. Xia and colleagues show that lapatinib unexpectedly activated RelA/NF-κB in ErbB2+ breast cancer cell lines and in ErbB2+ breast cancer patients. Inhibition of RelA phosphorylation led to increased apoptosis in lapatinib-treated ErbB2+ breast cancer cells. Furthermore, increased phospho-RelA expression in tumors treated with lapatinib monotherapy correlated with a poorer clinical outcome in ErbB2+ breast cancer patients. These findings identify RelA as a promising therapeutic target to enhance the clinical efficacy of lapatinib in ErbB2+ breast cancers.

Plk1 for Gemcitabine Resistance in Pancreatic Cancer

Jimeno et al., Page 311

Approaches to improve standard chemotherapeutic regimens by defining combinations are still empiric. Jimeno and colleagues evaluated a rational way of identifying relevant targets involved in the vulnerability of pancreatic cancer to gemcitabine. Pancreatic xenograft samples with known gemcitabine sensitivity were dynamically interrogated by exposure to gemcitabine and analysis of a preselected set of druggable genes. This identified Plk1 as a target dictating the susceptibility of pancreatic cancer to gemcitabine. Mechanistic studies aimed at testing this hypothesis were conducted utilizing gene interference and pharmacologic Plk1 inhibition, followed by in vivo testing in a direct xenograft model of pancreatic cancer.

Brivanib Antiangiogenesis Activity in Human Xenografts

Bhide et al., Page 369

Brivanib is an oral, dual selective inhibitor of VEGF and FGF signaling under clinical investigation. Bhide and colleagues evaluated the antitumor activity and antiangiogenic activities of brivanib and its prodrug brivanib alaninate in xenograft models and Matrigel plug assays in athymic mice. Brivanib and brivanib alaninate demonstrated potent antitumor and antiangiogenic activity over multiple dose levels in a broad range of tumor types. Further, brivanib alaninate inhibited angiogenesis driven by VEGF or bFGF alone, or when both growth factors were combined. This data supports the utility of targeting both VEGF- and FGF-induced angiogenesis in solid tumors.

  • ©2010 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 9 (2)
February 2010
Volume 9, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther February 1 2010 (9) (2) vii;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther February 1 2010 (9) (2) vii;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Cancer Cell Line Evolution
    • RelA-Mediated Acquired Resistance to Lapatinib
    • Plk1 for Gemcitabine Resistance in Pancreatic Cancer
    • Brivanib Antiangiogenesis Activity in Human Xenografts
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement